Shortcuts

open access

Vol 6, No 2 (2010)
Prace oryginalne
Published online: 2010-07-12
Get Citation

The treatment of severe growth failure in children with juvenile idiopathic arthritis and growth hormone deficiency - preliminary results

Małgorzata Wójcik, Agata Zygmunt-Górska, Magdalena Wąs, Katarzyna Doleżal-Ołtarzewska, Jerzy Starzyk
Endokrynol. Otył. Zab. Przem. Mat 2010;6(2):67-71.

open access

Vol 6, No 2 (2010)
Prace oryginalne
Published online: 2010-07-12

Abstract


INTRODUCTION. Short stature is one of the major, nonspecific features of juvenile idiopathic arthritis (JIA), that affects, in dependence on clinical presentation and severity, 11-90% of patients. The treatment with human recombinant growth hormone (rhGH) may be successful in almost 70% of such cases. the aim of the study was to analyze the initial results of the rhGH treatment in children with severe growth failure and GH deficiency secondary to JIA.
MATERIAL AND METHODS. From among 10 children (4 boys, 6 girls), age 6-15.5, mean 12.2 years, with growth deficiency [(-)7.7-(-2.4) the SDS], 5 (2 boys, 3 girls) with coexisting GH deficiency received rhGH treatment. All patients were treated with glucocorticoids (GCS) with a mean dosage of 0.08-1.4 mg/kg/day (prednisone), 3 of the patients treated with rhGH, and all non-treated patients received biological treatment (Etanercept).
RESULTS. After one year of rhGH treatment with a dosage of 0.03-0.06, mean 0.047 mg/kg/day) the growth velocity increased from 0–3.2, mean 1 cm/year, to 0.3-16, mean 3.3 cm/year, as well as the insulin like growth factor type 1 concentration from 69.1-331.1 (mean 197.5) ng/ml to 335-716,9 (mean 526) ng/ml. In 16.6 patient-years of treatment (5 patients, individual treatment period 1.8-4.5; mean 3.8 years) there was improvement of growth from 0.1 to 2.2 SD in 4 cases.
CONCLUSIONS. In patients with JIA undergoing rhGH treatment, with a dosage of approximately 0.047 mg/kg/day, improves growth velocity, and final height. The results may be different in individual cases. They are better if the growth failure before treatment is less severe, and the inflammation process is less active.
Endocrinology, Obesity and Metabolic Disorders 2010, vol. 6, No 2, 67-71

Abstract


INTRODUCTION. Short stature is one of the major, nonspecific features of juvenile idiopathic arthritis (JIA), that affects, in dependence on clinical presentation and severity, 11-90% of patients. The treatment with human recombinant growth hormone (rhGH) may be successful in almost 70% of such cases. the aim of the study was to analyze the initial results of the rhGH treatment in children with severe growth failure and GH deficiency secondary to JIA.
MATERIAL AND METHODS. From among 10 children (4 boys, 6 girls), age 6-15.5, mean 12.2 years, with growth deficiency [(-)7.7-(-2.4) the SDS], 5 (2 boys, 3 girls) with coexisting GH deficiency received rhGH treatment. All patients were treated with glucocorticoids (GCS) with a mean dosage of 0.08-1.4 mg/kg/day (prednisone), 3 of the patients treated with rhGH, and all non-treated patients received biological treatment (Etanercept).
RESULTS. After one year of rhGH treatment with a dosage of 0.03-0.06, mean 0.047 mg/kg/day) the growth velocity increased from 0–3.2, mean 1 cm/year, to 0.3-16, mean 3.3 cm/year, as well as the insulin like growth factor type 1 concentration from 69.1-331.1 (mean 197.5) ng/ml to 335-716,9 (mean 526) ng/ml. In 16.6 patient-years of treatment (5 patients, individual treatment period 1.8-4.5; mean 3.8 years) there was improvement of growth from 0.1 to 2.2 SD in 4 cases.
CONCLUSIONS. In patients with JIA undergoing rhGH treatment, with a dosage of approximately 0.047 mg/kg/day, improves growth velocity, and final height. The results may be different in individual cases. They are better if the growth failure before treatment is less severe, and the inflammation process is less active.
Endocrinology, Obesity and Metabolic Disorders 2010, vol. 6, No 2, 67-71
Get Citation

Keywords

Juvenile Idiopathic Arthritis; growth failure; growth hormone

About this article
Title

The treatment of severe growth failure in children with juvenile idiopathic arthritis and growth hormone deficiency - preliminary results

Journal

Endocrinology, Obesity and Metabolic Disorders

Issue

Vol 6, No 2 (2010)

Pages

67-71

Published online

2010-07-12

Bibliographic record

Endokrynol. Otył. Zab. Przem. Mat 2010;6(2):67-71.

Keywords

Juvenile Idiopathic Arthritis
growth failure
growth hormone

Authors

Małgorzata Wójcik
Agata Zygmunt-Górska
Magdalena Wąs
Katarzyna Doleżal-Ołtarzewska
Jerzy Starzyk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk,

tel. +48 58 320 94 94, faks +48 58 320 94 94, e-mail:  viamedica@viamedica.pl